Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1Pre-specified analyses of cognitive endpoints dem ...

Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s

Biogen Inc. (NASDAQ:BIIB) shares rose 10% Thursday after the company reported positive results from its Phase 2 CELIA study of diranersen, an experimental Alzheimer’s treatment targeting tau protein.

Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, ...
MarketBeat on MSN

Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA ...

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study

Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, ...

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of ...
ascopubs.org

Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A ...

Gemcitabine and cisplatin chemotherapy plus penpulimab combined with or without anlotinib as neoadjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A prospective, phase II clinical ...
Nasdaq

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...
The Manila Times

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung ...

Biogen Inc.: Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early ...

CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational developmentRobust reduct ...